top of page
Vantedge White Logo.png

Accelerating the Next Generation of Cancer Therapies.

About Vantedge

Vantedge Bioventures is a venture studio that brings together the science, talent, and funding to accelerate the development of the next generation of cancer therapies. By combining AI-driven discovery, experienced leadership, and advanced  preclinical development, we shorten development timelines, reduce costs, and improve success rates to bring new hope to patients with difficult-to-treat cancers.

Our Business Model

DNA Double Helix

Our proprietary Oncolix™ platform combines AI with deep biological and chemical insights to identify promising targets, prioritize drug candidates, and guide development decisions—helping each venture advance with greater speed and precision.

AI Driven Discovery

We work with our co-founding teams to build compelling investment opportunities and connect with investors aligned with each venture’s potential. Funding is structured around development milestones to support progress, manage risk, and build value.

Venture Funding

We partner with proven drug development entrepreneurs and scientific leaders to build focused oncology companies. Together, we unite scientific expertise, business strategy, and execution to move promising discoveries toward meaningful milestones.

Experienced Leadership

Our integrated scientific and wet-lab capabilities support each venture from target validation through IND-enabling development. By coordinating biology, chemistry, and specialized development expertise, we help shorten timelines, control costs, and prepare promising therapies for clinical evaluation.

Advanced Preclinical Development

Current Projects

 High Incident Cancers

Lung Cancer (NSCLC/SCLC

Breast Cancer (TNBC)

Colorectal Cancer

Prostate Cancer

Gastric & Stomach Cancer

Liver Cancer (HCC)

Pancreatic Cancer

Bladder/Kidney Cancer

Endometrial /Ovarian Cancer

Rare Cancers

Sarcomas

Mesothelioma
Cholangialcarcinoma
Thymic Carcinoma
Adrenocortical  Carcinoma
Uveal Melanoma
Merkel Cell Carcinoma
Salivary Gland Cancers
Rare Neuroendocrine Cancers

Competitive Advantages

Every company we launch has access to Oncolix™, our powerful AI-driven drug development platform—built to accelerate discovery, streamline preclinical development, and lower costs while advancing therapies with greater potential to improve patient outcomes.

Oncolix™ combines AI-driven discovery with integrated preclinical development to target an 18–36-month path to IND readiness—approximately 2–3× faster than traditional approaches

Accelerated Timing

1

By prioritizing promising candidates and focusing experimental work, Oncolix™ aims to reduce preclinical development costs by 60–80%, helping investment go further.

Improved Outcomes

Lower Cost

2

Oncolix™ uses biological insights and biomarker-driven patient selection to identify therapies and combinations with greater potential for clinical success. Targeted benefits include 2–4× higher responder rates and 25–50% smaller clinical trials, subject to clinical validation.

Improved Outcomes

3

Contact Us

Interested in leading one of our portfolio companies?  Connect with us to explore a partnership.

Timothy Hamill, CEO

Vantedge Bioventures

timothy.hamill@vantedgebioventures.com

(313) 717-3973

Subscribe to our newsletter

bottom of page